389 related articles for article (PubMed ID: 25471551)
1. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra.
Saunier J; Debarbieux S; Jullien D; Garnier L; Dalle S; Thomas L
Dermatology; 2015; 230(2):97-100. PubMed ID: 25471551
[TBL] [Abstract][Full Text] [Related]
2. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.
Lutz V; Lipsker D
Arch Dermatol; 2012 Mar; 148(3):297-9. PubMed ID: 22431771
[No Abstract] [Full Text] [Related]
3. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents.
Adışen E; Özer İ; Temel B; Gürer MA
Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 28139054
[TBL] [Abstract][Full Text] [Related]
4. Acrodermatitis continua of Hallopeau response to optimized biological therapy.
Adas A; Dadban A; Arnault JP; Chaby G; Lok C
Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865417
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review.
Puig L; Barco D; Vilarrasa E; Alomar A
Dermatology; 2010; 220(2):154-8. PubMed ID: 20110631
[TBL] [Abstract][Full Text] [Related]
7. A recalcitrant acrodermatitis continua of Hallopeau successfully treated with etanercept.
Silpa-archa N; Wongpraparut C
J Med Assoc Thai; 2011 Sep; 94(9):1154-7. PubMed ID: 21970208
[TBL] [Abstract][Full Text] [Related]
8. Acrodermatitis continua of Hallopeau successfully treated with secukinumab.
Balestri R; Rech G; Tasin L; Rizzoli L; Girardelli CR
J Dermatolog Treat; 2018; 29(sup1):3-5. PubMed ID: 30246571
[TBL] [Abstract][Full Text] [Related]
9. Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and acitretin combination therapy.
Byekova Y; Sami N
J Dermatol; 2015 Aug; 42(8):830-1. PubMed ID: 25982628
[No Abstract] [Full Text] [Related]
10. Successful treatment of recalcitrant acrodermatitis continua of Hallopeau with adalimumab and acitretin.
Tobin AM; Kirby B
Br J Dermatol; 2005 Aug; 153(2):445-6. PubMed ID: 16086767
[No Abstract] [Full Text] [Related]
11. Acrodermatitis continua of Hallopeau: response to combined treatment with acitretin and calcipotriol ointment.
Kuijpers AL; van Dooren-Greebe RJ; van de Kerkhof PC
Dermatology; 1996; 192(4):357-9. PubMed ID: 8864375
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy after failure of anti-TNF agents.
Palacios-Álvarez I; Simal-Gómez G; Mas-Vidal A; Bernad-Alonso I
J Dtsch Dermatol Ges; 2018 May; 16(5):611-613. PubMed ID: 29659137
[No Abstract] [Full Text] [Related]
13. The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of hallopeau.
Kazinski K; Joyce KM; Hodson D
J Drugs Dermatol; 2005; 4(3):360-4. PubMed ID: 15898294
[TBL] [Abstract][Full Text] [Related]
14. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.
Maliyar K; Crowley EL; Rodriguez-Bolanos F; O'Toole A; Gooderham MJ
J Cutan Med Surg; 2019; 23(4):428-435. PubMed ID: 30938189
[TBL] [Abstract][Full Text] [Related]
15. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
16. Etanercept and recalcitrant acrodermatitis continua of Hallopeau.
Nikkels AF; Piérard GE
J Drugs Dermatol; 2006 Sep; 5(8):705-6. PubMed ID: 16991229
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau.
Husson B; Barbe C; Hegazy S; Seneschal J; Aubin F; Mahé E; Jullien D; Sbidian E; D'Incan M; Conrad C; Brenaut E; Girard C; Richard MA; Bachelez H; Viguier M;
J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2330-2338. PubMed ID: 32030802
[TBL] [Abstract][Full Text] [Related]
18. The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
Tabolli S; Giannantoni P; Paradisi A; Abeni D
Br J Dermatol; 2015 Jul; 173(1):256-8. PubMed ID: 25422080
[No Abstract] [Full Text] [Related]
19. Treatment of acrodermatitis continua of hallopeau with ixekizumab.
Miller AC; Holland TE; Cohen DJ
J Dermatolog Treat; 2021 Feb; 32(1):117-119. PubMed ID: 31184530
[TBL] [Abstract][Full Text] [Related]
20. Acrodermatitis Continua of Hallopeau with Psoriatic Arthritis.
Khosravi-Hafshejani T; Zhou Y; Dutz JP
J Rheumatol; 2019 Apr; 46(4):437-438. PubMed ID: 30936225
[No Abstract] [Full Text] [Related]
[Next] [New Search]
